-
2
-
-
0035888074
-
Estimating the world cancer burden: Globocan 2000
-
Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
-
(2001)
Int J Cancer
, vol.94
, pp. 153-156
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
3
-
-
2342591455
-
The discovery of receptor tyrosine kinases: targets for cancer therapy
-
Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
4
-
-
0032915392
-
Epidermal growth factor receptors: critical mediators of multiple receptor pathways
-
Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11:184-189.
-
(1999)
Curr Opin Cell Biol
, vol.11
, pp. 184-189
-
-
Hackel, P.O.1
Zwick, E.2
Prenzel, N.3
Ullrich, A.4
-
5
-
-
0034638917
-
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
-
Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19:6115-6121.
-
(2000)
Oncogene
, vol.19
, pp. 6115-6121
-
-
Yu, D.1
Hung, M.C.2
-
6
-
-
37049183697
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
7
-
-
0032563825
-
Doxorubicin-induced cardiomyopathy
-
Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
-
(1998)
N Engl J Med
, vol.339
, pp. 900-905
-
-
Singal, P.K.1
Iliskovic, N.2
-
8
-
-
0015849162
-
A clinicopathologic analysis of adriamycin cardiotoxicity
-
Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
-
(1973)
Cancer
, vol.32
, pp. 302-314
-
-
Lefrak, E.A.1
Pitha, J.2
Rosenheim, S.3
Gottlieb, J.A.4
-
9
-
-
0034820943
-
Anthracycline-induced cardiomyopathy
-
Keefe D.L. Anthracycline-induced cardiomyopathy. Semin Oncol 2001, 28(4 suppl 11):2-7.
-
(2001)
Semin Oncol
, vol.28
, Issue.4 SUPPL. 11
, pp. 2-7
-
-
Keefe, D.L.1
-
10
-
-
34248573600
-
Managing cardiotoxicity in anthracycline-treated breast cancers
-
Ng R., Green M.D. Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin Drug Saf 2007, 6:315-321.
-
(2007)
Expert Opin Drug Saf
, vol.6
, pp. 315-321
-
-
Ng, R.1
Green, M.D.2
-
11
-
-
0018102512
-
Anthracycline cardiomyopathy monitored by morphologic changes
-
Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865-872.
-
(1978)
Cancer Treat Rep
, vol.62
, pp. 865-872
-
-
Billingham, M.E.1
Mason, J.W.2
Bristow, M.R.3
Daniels, J.R.4
-
12
-
-
0026610881
-
Humanization of an anti-p185HER2 antibody for human cancer therapy
-
Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
-
(1992)
Proc Natl Acad Sci U S A
, vol.89
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
-
13
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
14
-
-
0034183463
-
New strategies for managing metastatic breast cancer
-
Olin J.J., Muss H.B. New strategies for managing metastatic breast cancer. Oncology (Williston Park) 2000, 14:629-641.
-
(2000)
Oncology (Williston Park)
, vol.14
, pp. 629-641
-
-
Olin, J.J.1
Muss, H.B.2
-
15
-
-
0035869407
-
Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized control trial
-
Slamon D.J., Leyland-Jones B., Shak S., et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized control trial. N Engl J Med 2001, 344:783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
16
-
-
26844503270
-
Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
17
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
18
-
-
43849094005
-
Cardiotoxicity profile of Trastuzumab
-
Ewer S.M., Ewer M.S. Cardiotoxicity profile of Trastuzumab. Drug Saf 2008, 31:459-467.
-
(2008)
Drug Saf
, vol.31
, pp. 459-467
-
-
Ewer, S.M.1
Ewer, M.S.2
-
19
-
-
58149250715
-
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)
-
Guarneri V., Frassoldati A., Bruzzi P., et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008, 8:453-456.
-
(2008)
Clin Breast Cancer
, vol.8
, pp. 453-456
-
-
Guarneri, V.1
Frassoldati, A.2
Bruzzi, P.3
-
20
-
-
33845914783
-
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
-
Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
-
(2007)
Lancet
, vol.369
, pp. 29-36
-
-
Smith, I.1
Procter, M.2
Gelber, R.D.3
-
21
-
-
33745615786
-
Herceptin (trastuzumab): adjuvant and neoadjuvant trials
-
Yaal-Hahoshen N., Safra T. Herceptin (trastuzumab): adjuvant and neoadjuvant trials. Isr Med Assoc J 2006, 8:416-421.
-
(2006)
Isr Med Assoc J
, vol.8
, pp. 416-421
-
-
Yaal-Hahoshen, N.1
Safra, T.2
-
22
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
-
(2006)
N Engl J Med
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Bono, P.3
-
23
-
-
68949121146
-
Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study
-
Wadhwa D., Fallah-Rad N., Grenier D., et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009, 117:357-364.
-
(2009)
Breast Cancer Res Treat
, vol.117
, pp. 357-364
-
-
Wadhwa, D.1
Fallah-Rad, N.2
Grenier, D.3
-
24
-
-
77955294878
-
The role of 3D echocardiography in breast cancer: comparison with 2D echocardiography, MUGA and cardiac MRI
-
Walker J.R., Bhullar N., Fallah-Rad N., et al. The role of 3D echocardiography in breast cancer: comparison with 2D echocardiography, MUGA and cardiac MRI. J Clin Oncol 2010, 28:3429-3436.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3429-3436
-
-
Walker, J.R.1
Bhullar, N.2
Fallah-Rad, N.3
-
25
-
-
79957576807
-
The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant trastuzumab therapy
-
Fallah-Rad N., Walker J.R., Wassef A., et al. The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011, 57:2263-2270.
-
(2011)
J Am Coll Cardiol
, vol.57
, pp. 2263-2270
-
-
Fallah-Rad, N.1
Walker, J.R.2
Wassef, A.3
-
26
-
-
0032796535
-
Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy
-
Iliskovic N., Hasinoff B.B., Malisza K.L., et al. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem 1999, 196:43-49.
-
(1999)
Mol Cell Biochem
, vol.196
, pp. 43-49
-
-
Iliskovic, N.1
Hasinoff, B.B.2
Malisza, K.L.3
-
27
-
-
0343554684
-
Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat
-
Luo X., Evrovsky Y., Cole D., et al. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochem Biophys Acta 1997, 1360:45-52.
-
(1997)
Biochem Biophys Acta
, vol.1360
, pp. 45-52
-
-
Luo, X.1
Evrovsky, Y.2
Cole, D.3
-
28
-
-
0030855953
-
Adriamycin cardiomyopathy: pathophysiology and prevention
-
Singal P.K., Iliskovic N., Li T., Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997, 11:931-936.
-
(1997)
FASEB J
, vol.11
, pp. 931-936
-
-
Singal, P.K.1
Iliskovic, N.2
Li, T.3
Kumar, D.4
-
29
-
-
9644310269
-
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy
-
Grazette L.P., Boecker W., Matsui T., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004, 44:2231-2238.
-
(2004)
J Am Coll Cardiol
, vol.44
, pp. 2231-2238
-
-
Grazette, L.P.1
Boecker, W.2
Matsui, T.3
-
30
-
-
59049093631
-
Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways
-
Gordon L.I., Burke M.A., Singh A.T., et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009, 284:2080-2087.
-
(2009)
J Biol Chem
, vol.284
, pp. 2080-2087
-
-
Gordon, L.I.1
Burke, M.A.2
Singh, A.T.3
-
31
-
-
34548403111
-
Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin
-
Neilan T.G., Blake S.L., Ichinose F., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514.
-
(2007)
Circulation
, vol.116
, pp. 506-514
-
-
Neilan, T.G.1
Blake, S.L.2
Ichinose, F.3
-
32
-
-
79956368032
-
The cardioprotective role of probucol against anthracycline and trastuzumab mediated cardiotoxicity
-
Walker J.R., Sharma A., Lytwyn M., et al. The cardioprotective role of probucol against anthracycline and trastuzumab mediated cardiotoxicity. J Am Soc Echocardiogr 2011, 24:699-705.
-
(2011)
J Am Soc Echocardiogr
, vol.24
, pp. 699-705
-
-
Walker, J.R.1
Sharma, A.2
Lytwyn, M.3
-
33
-
-
74549224505
-
The art of healing broken hearts in breast cancer: trastuzumab and heart failure
-
Walker J.R., Singal P.K., Jassal D.S. The art of healing broken hearts in breast cancer: trastuzumab and heart failure. Exp Clin Cardiol 2009, 14:e62-e67.
-
(2009)
Exp Clin Cardiol
, vol.14
-
-
Walker, J.R.1
Singal, P.K.2
Jassal, D.S.3
-
34
-
-
8144229686
-
Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice
-
Nozaki N., Shishido T., Takeishi Y., Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004, 110:2869-2874.
-
(2004)
Circulation
, vol.110
, pp. 2869-2874
-
-
Nozaki, N.1
Shishido, T.2
Takeishi, Y.3
Kubota, I.4
-
35
-
-
58349097915
-
Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice
-
Riad A., Bien S., Westermann D., et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 2009, 69:695-699.
-
(2009)
Cancer Res
, vol.69
, pp. 695-699
-
-
Riad, A.1
Bien, S.2
Westermann, D.3
-
36
-
-
63249107117
-
Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy
-
Jassal D.S., Han S.Y., Hans C., et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009, 22:418-424.
-
(2009)
J Am Soc Echocardiogr
, vol.22
, pp. 418-424
-
-
Jassal, D.S.1
Han, S.Y.2
Hans, C.3
-
37
-
-
70349317477
-
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents
-
Riccio G., Esposito G., Leoncini E., et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 2009, 23:3171-3178.
-
(2009)
FASEB J
, vol.23
, pp. 3171-3178
-
-
Riccio, G.1
Esposito, G.2
Leoncini, E.3
-
38
-
-
80053995420
-
Novel toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
-
Yousif N.G., Al-Amran F.G. Novel toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord 2011, 11:62.
-
(2011)
BMC Cardiovasc Disord
, vol.11
, pp. 62
-
-
Yousif, N.G.1
Al-Amran, F.G.2
-
39
-
-
84863726300
-
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
-
Fedele C., Riccio G., Coppola C., et al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat 2012, 133:511-521.
-
(2012)
Breast Cancer Res Treat
, vol.133
, pp. 511-521
-
-
Fedele, C.1
Riccio, G.2
Coppola, C.3
-
40
-
-
21144436077
-
Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry
-
Sebag I.A., Handschumacher M.D., Ichinose F., et al. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 2005, 111:2611-2616.
-
(2005)
Circulation
, vol.111
, pp. 2611-2616
-
-
Sebag, I.A.1
Handschumacher, M.D.2
Ichinose, F.3
-
41
-
-
70449158340
-
A simple method for the isolation and purification of total lipides from animal tissues
-
Folch J., Lees M., Sloane Stanley G. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
-
(1957)
J Biol Chem
, vol.226
, pp. 497-509
-
-
Folch, J.1
Lees, M.2
Sloane Stanley, G.3
-
42
-
-
84869074308
-
Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions
-
van Dijk R.A., Kolodgie F., Ravandi A., et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012, 53:2773-2790.
-
(2012)
J Lipid Res
, vol.53
, pp. 2773-2790
-
-
van Dijk, R.A.1
Kolodgie, F.2
Ravandi, A.3
-
43
-
-
0042858394
-
Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells
-
Loidl A., Sevcsik E., Riesenhuber G., Deigner H.P., Hermetter A. Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. J Biol Chem 2003, 278:32921-32928.
-
(2003)
J Biol Chem
, vol.278
, pp. 32921-32928
-
-
Loidl, A.1
Sevcsik, E.2
Riesenhuber, G.3
Deigner, H.P.4
Hermetter, A.5
-
45
-
-
78650679530
-
Distinct role and location of the endothelial isoform of nitric oxide synthase 3 in regulating platelet aggregation in males and females in vivo
-
Moore C., Sanz-Rosa D., Emerson M. Distinct role and location of the endothelial isoform of nitric oxide synthase 3 in regulating platelet aggregation in males and females in vivo. Eur J Pharmacol 2011, 651:152-158.
-
(2011)
Eur J Pharmacol
, vol.651
, pp. 152-158
-
-
Moore, C.1
Sanz-Rosa, D.2
Emerson, M.3
-
46
-
-
69349095566
-
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial
-
Choi J.Y., Barlow W.E., Albain K.S., et al. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res 2009, 15:5258-5266.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5258-5266
-
-
Choi, J.Y.1
Barlow, W.E.2
Albain, K.S.3
|